Treatment with MSC-derived exosomes containing miR-124a reduce the viability and clonogenicity of glioma stem cell lines in vitro and increase the survival rate in glioma mouse models up to 50% by silencing FOXA2 (62), while the loading of MSC exosomes with miR-143 acts to significantly reduce the migration of 143B osteosarcoma cells (80). This evidence concerns the gene FOXA2 and central nervous system cancer.